Literature DB >> 22923271

Trends in Fidelis lead survival: transition from an exponential to linear pattern of lead failure over time.

Jim W Cheung1, Aviva Tobin-Hess, Apoor Patel, David J Slotwiner, Bruce G Goldner.   

Abstract

BACKGROUND: The Sprint Fidelis implantable cardioverter-defibrillator lead was recalled in 2007 because of an levated risk of lead fracture. Several studies have demonstrated an accelerating risk of lead failure over time. We sought to identify predictors and characterize trends of Fidelis lead failure. METHODS AND
RESULTS: We evaluated 604 Fidelis leads with ≥ 90 days of follow-up implanted at our institution. Fidelis lead survival was analyzed by the Kaplan-Meier method. Analysis of log-log plots of cumulative hazard plots was performed to assess changes in lead failure rate over time. During follow-up of 3.3 ± 1.7 years, 51 (8.4%) Fidelis lead failures were identified. The 3-year and 5-year Fidelis lead survival rates were 93.5% and 85.3%, respectively. Female sex was the only significant predictor of lead failure (heart rate, 2.1; 95% CI, 1.1-3.9; P<0.0001). The rate of lead failure initially increased exponentially with a power of 2.3 (95% CI, 2.22-2.43; P<0.0001). However, log-log analysis of cumulative hazard for leads functioning at 2 and 4 years revealed a stable rate of failure of 4.5%/year. Mathematical modeling of the Fidelis lead failure demonstrated a transition from an exponential to linear pattern of lead failure at 2.9 years.
CONCLUSIONS: After 3 years, failure rates of Fidelis leads stabilize but at a significantly elevated rate. Female sex is associated with a doubling of the risk of Fidelis lead failure. These findings have implications for Fidelis lead management decisions that are based on the prediction of lead failure risk.

Entities:  

Mesh:

Year:  2012        PMID: 22923271     DOI: 10.1161/CIRCEP.112.972000

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  4 in total

1.  Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE.

Authors:  Emily P Zeitler; Daniel J Friedman; Zak Loring; Kristen B Campbell; Sarah A Goldstein; Zachary K Wegermann; Jane Schutz; Nicole Smith; Eric Black-Maier; Sana M Al-Khatib; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2019-09-24       Impact factor: 6.343

Review 2.  Adverse events following implantable cardioverter defibrillator implantation: a systematic review.

Authors:  Rebecca Persson; Amy Earley; Ann C Garlitski; Ethan M Balk; Katrin Uhlig
Journal:  J Interv Card Electrophysiol       Date:  2014-06-20       Impact factor: 1.900

3.  Clinical and radiographic predictors of cardiovascular implantable electronic device lead failure at the time of initial implantation.

Authors:  Eun-Jeong Kim; Giovanni Davogustto; Shi Huang; George H Crossley; Jay A Montgomery
Journal:  J Arrhythm       Date:  2021-06-07

4.  Prospective long-term follow-up of silicone-polyurethane-insulated implantable cardioverter-defibrillator leads.

Authors:  John A Cairns; Jeff S Healey; Andrew E Epstein; Ellison Themeles; Kumar Balasubramanian; Stuart J Connolly
Journal:  Heart Rhythm O2       Date:  2021-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.